Week in Review: Shanghai Regor to Discover Metabolic Therapies for Lilly in $1.55 Billion Deal
publication date: Dec 11, 2021
Deals and Financings
- Shanghai Regor Therapeutics entered a $1.55 billion research pact with Eli Lilly to discover novel therapies for metabolic disorders;
- Beijing Avistone Pharma, a precision oncology company, received a $200 million strategic investment led by Vivo Capital to combine with Pearl Biotech;
- Hangzhou Innoforce brought its Series A round to $157 million with a $59 million tranche for its biopharma development/manufacturing operations;
- METiS Therapeutics, a Cambridge, MA AI company, raised $86 million in a Series A Round from China investors;
- CANbridge Pharma of Shanghai completed a $77 million Hong Kong IPO to develop its rare disease candidates;
- RareStone, a Shanghai-Boston company, in-licensed greater China rights to a therapy for genetic obesity from Rhythm Pharma in a $75 million agreement;
- Xcovery, a Florida biopharma backed by Hangzhou's Betta Pharma, acquired a controlling stake in Meryx, a North Carolina immuno-oncology company;
- Tianjin CanSinoBIO partnered with Ireland's Aerogen to supply inhalers for its nasal coronavirus therapy;
Trials and Approvals
- Beijing Brii Biosciences reported China approved its combination mAb therapy for patients with mild COVID-19 at risk for disease progression;
- Shanghai I-Mab said the first patient has been dosed in a US Phase I study of Protollin, a novel immune therapy for Alzheimer's disease.
Stock Symbols: (NYSE: LLY) (HK: 1228) (SHA: 688185, HK: 06185) (HK: 2137) (NSDQ: IMAB)
Share this with colleagues:
Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?
If you are already a subscriber, please login.
If you believe you should have received this message in error, please contact us.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.